ArticleCytokine2021
Characterizing the immune responses of those who survived or succumbed to COVID-19: Can immunological signatures predict outcome?
Article in Cytokine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Effects of antiphospholipid antibodies in the severity and outcome of COVID-19.BMC infectious diseases · 2026Article
- Association of SARS-CoV-2 infection with long-lasting increase in circulating IL-32 levels.Frontiers in immunology · 2026Observational
- Immunomodulatory effect of CD71BMC nephrology · 2025Article
- How does the Immunological System Change during the SARS-COV-2 Attack? A Clue for the New Immunotherapy Discovery.Current medicinal chemistry · 2025Review
- Molecular modeling to design a multiepitope vaccine against emerging tick-borne Yezo virus and its validation through biophysics techniques.In silico pharmacology · 2025Article
- Immune landscape and redox imbalance during neurological disorders in COVID-19.Cell death & disease · 2023Review
- Recognition of Differentially Expressed Molecular Signatures and Pathways Associated with COVID-19 Poor Prognosis in Glioblastoma Patients.International journal of molecular sciences · 2023Article
- Simulation of COVID-19 symptoms in a genetically engineered mouse model: implications for the long haulers.Molecular and cellular biochemistry · 2023Article
- A scoping review of regulatory T cell dynamics in convalescent COVID-19 patients - indications for their potential involvement in the development of Long COVID?Frontiers in immunology · 2022Article
- High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients.Pathogens (Basel, Switzerland) · 2021Article
- COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators.Immunologic research · 2021Article
- COVID-19: captures iron and generates reactive oxygen species to damage the human immune system.Autoimmunity · 2021Article
- Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-Clinical case reports · 2021Article
- SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models.Frontiers in pharmacology · 2021Review
- Post-discharge Thromboembolic Events in COVID-19 Patients: A Review on the Necessity for Prophylaxis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
- Predicting roles of IL-27 and IL-32 in determining the severity and outcome of COVID-19.International journal of immunopathology and pharmacologyArticle
- Changes in immune profile affect disease progression in hepatocellular carcinoma.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunodeficiency has pivotal role in the pathogenesis of coronavirus disease 2019 (COVID-19). Several studies have indicated defects in the immune system of COVID-19 patients at different disease stages. Therefore, this study investigated whether alters in immune responses of COVID-19 patients may be considered as predicting factors for disease outcome.
methodsThe percentages of innate and adoptive immune cells in the recovered and dead patients with COVID-19, and healthy subjects were determined by flow cytometry. The levels of pro- and anti-inflammatory cytokines and other immune factors were also measured by enzyme-linked immunosorbent assay.
resultsAt the first day of hospitalization, the frequencies of CD56
conclusionChanges in frequencies of some immune cells and levels of some immune factors may be considered as predictors of mortality in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.